Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.47 |
| ▸ | KDR | P35968 | 9/20 | 0.43 |
| ▸ | MET | P08581 | 6/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636743 | 0.88 | GRM5 (0.50) | GRM5KDRMETNPC1RAB9A | |
| SCHEMBL3632867 | 0.86 | KDR (0.54) | GRM5KDRMETNPC1KDM4E | |
| SCHEMBL27801687 | 0.84 | NPC1 (0.48) | GRM5KDRMETPARP1NPC1 | |
| SCHEMBL3336522 | 0.79 | NPC1 (0.57) | NPC1KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4516647 | 0.76 | GRM5 (0.57) | GRM5KDRMETMEN1KMT2A | |
| SCHEMBL4505307 | 0.76 | GRM5 (0.57) | GRM5MAPT | |
| SCHEMBL3634023 | 0.73 | GRM5 (0.59) | GRM5KDRNPC1RAB9AMAPT | |
| SCHEMBL4518773 | 0.72 | GRM5 (0.61) | GRM5KDRNPC1ALDH1A1RAB9A | |
| SCHEMBL3637525 | 0.71 | GRM5 (0.61) | GRM5KDRRAB9AMEN1KMT2A | |
| SCHEMBL3632289 | 0.71 | GRM5 (0.66) | GRM5NPC1ALDH1A1RAB9ACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | GRM5 4545/4885KDR 4616/4885MET 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.